A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

Overview of attention for article published in Frontiers in immunology, December 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 18 news stories from 18 outlets.

SAN DIEGO--(BUSINESS WIRE)-- AvantGen, Inc., a San Diego-based biotechnology company with an array of technology platforms for…

Jan. 11, 2021 23:59 UTC SAN DIEGO--( BUSINESS WIRE )-- AvantGen, Inc., a San Diego-based biotechnology company with an array of…

| Spoke AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development SAN…

Under the licensing agreement, AvantGen grants IGM Biosciences the rights to convert the antibody clones into IgA or IgM format…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 14 additional news stories.